Sun Pharmaceutical Industries (SUNPHARMA) Investor presentation summary

Business overview and global presence

• Operates in over 100 countries with 41 manufacturing facilities and a workforce of 43,000+ employees.

• Largest pharmaceutical company in India and 13th largest in US generics market.

• Diversified business across global specialty, US generics, India, emerging markets, and rest of world.

• Specialty, branded generics, generics, and APIs form the core portfolio.

• Expanding presence in ex-US developed markets and maintaining quality compliance.

Revenue composition and growth

• FY24 sales reached Rs 478 Bn, with US formulations (32%) and India branded formulations (31%) as top contributors.

• Sales CAGR of 18% from FY09 to FY24, with EBITDA and net profit CAGR at 14% and 12% respectively.

• Gross margin improved to 77.7% in FY24, with EBITDA margin at 26.9%.

• Market capitalization at US $45 Bn as of July 2024.

• Strong cash flow and reduced gross debt over recent years.

Segment performance

• US business: Rs 153,493 mn sales in FY24, 13th largest generics company, robust specialty pipeline.

• India business: Rs 148,893 mn sales, 8.5% market share, No.1 by prescriptions in 12 classes.

• Emerging markets: Rs 86,195 mn sales, presence in 80+ countries, focus on branded generics.

• Rest of World: Rs 67,128 mn sales, expanding specialty and hospital product portfolio.

• API & others: 5% of FY24 revenues, 380 APIs, strong backward integration.